A Phase 4 interventional study of Corticosteroid injection (CSI) and Low-dose radiotherapy (LDRT) in Osteoarthritis Hand and Osteoarthritis Wrist, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Mayo Clinic · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Osteoarthritis by Mayo Clinic — 2 open to participants now, 4 under way, 1 of them phase 3. Osteoarthritis · Mayo Clinic.
Among the 21 studies in Osteoarthritis by Mayo Clinic, this one is the 4th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 4, and was the 21st registered.
2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →2 of the 21 studies in Osteoarthritis by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 40+
By country, each count listing its studies:
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 2 · Phase 4 3
First in 2002; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 165 is above the median of 80 across 2,242 interventional studies indexed under Osteoarthritis.
Median enrollment 40 across the 19 interventional studies, 98 across the 2 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
2 of the studies in Osteoarthritis by Mayo Clinic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05992883Phase 3Mayo ClinicNSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis | 2026-12-31 |
| NCT07217405Mayo ClinicRadiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Osteoarthritis by Mayo Clinic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to compare low-dose radiotherapy to corticosteroid injection for treatment of hand/wrist osteoarthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive a total of six (6) low-dose radiotherapy (LDRT) treatments for hand osteoarthritis.
Radiation: Low-dose radiotherapy (LDRT)
Subjects will receive standard of care corticosteroid injection (CSI) therapy for hand osteoarthritis.
Drug: Corticosteroid injection (CSI)
A maximum of 3 joints will be treated with standard a standard combination of methylprednisolone and lidocaine: * 1st Carpometacarpal (CMC) joint - 20 mg methylprednisolone/0.5 mL 1% lidocaine\* * Radiocarpal (RC) joint - 40 mg methylprednisolone/1 mL 1% lidocaine\* * Scaphotrapeziotrapezoidal (STT) joint - 20 mg methylprednisolone/0.5 mL 1% lidocaine\* * Metacarpophalangeal (MCP) joint - 20 mg methylprednisolone/0.5 mL 1% lidocaine * Interphalangeal (IP) joint - 10 mg methylprednisolone/0.25 mL 1% lidocaine
Also known as: Methylprednisolone, Lidocaine
Subjects will be treated with low-dose radiotherapy of 300cGy in 6 fractions, 2-3 times per week on non-consecutive days. Non-responders to the initial LDRT treatment will receive a second treatment course of 300cGy in 6 fractions to be given 2-3 times per week on non-consecutive days.
Change in Visual Analog Scale (VAS) score
Pain values reported by participants will be assessed using the 100-mm Visual Analogue Scale (VAS). The VAS line will be 100 mm long with no intermediate delineations. Each end will be marked with "no pain" on the left, and "worst possible pain" on the right. Participants will identify their pain level by indicating a point on the line between each end. That point will be measured from the "No pain" end, and the number of millimeters will be reported as the pain score.
Time frame: Baseline, monthly for 6 months post-intervention, 9 months post-intervention, 12 months post-intervention
Change in Cochin Hand Function Scale scores
The Cochin Hand Function Scale (CHFS) uses an 18-item, 5-point Likert scale (0 to 5) for scoring, where higher scores indicate greater difficulty with hand function. Scores range from 0 (no difficulty) to 90 (impossible to complete) by summing the ratings for all 18 items. This scale measures the ability to perform daily activities related to the hand, such as kitchen tasks, dressing, and hygiene.
Time frame: Baseline, monthly for 6 months post-intervention, 9 months post-intervention, 12 months post-intervention
Change in analgesic medication use
Change in analgesic medication use will be assessed using the Qualitative Analgesic Questionnaire \[QAC\]. The QAC is a 3 question self-report survey tracking current use of pain medications.
Time frame: Baseline, monthly for 6 months post-intervention, 9 months post-intervention, 12 months post-intervention
Patient experience, as measured by Was It Worth It questionnaire
The Was It Worth It questionnaire is a 4-question survey consisting of yes/no questions regarding the treatment experience. The greater number of questions with a 'yes' response indicate a higher level of patient satisfaction.
Time frame: 6 months and 12 months post-intervention
Plan to share: No
Started Dec 2025 (actual). Primary completion is estimated for May 2027, 16 months after the start.
Of 54 non-industry phase 4 interventional studies under Osteoarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's planned 16 months is below that.
Counting every sponsor, half of 63 studies reached it within 28 months; a quarter within 11 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.